BIOR (Biora Therapeutics Inc.) רווח למניה בארבעת הרבעונים האחרונים

Biora Therapeutics (BIOR) protects its smart capsule development with patents, creating a barrier to entry in the niche. The YoY TTM earnings per share dynamics visualize the current trend, where 44.00 determines the latest valuation metric. Distributed laboratories ensure business resilience, while diversification into chronic gastrointestinal inflammation therapies allows the company to effectively minimize medical risks.
BIOR (Biora Therapeutics): פילוחים אנליטיים ודוחות לפי אינדיקטורים

The expansion of DDS drug delivery platforms at Biora Therapeutics (BIOR) directly correlates with the annual trend of EPS TTM YoY. This indicator measures the percentage change in net income per share over the last twelve months relative to the previous year. The calculation is based on a comparison of current financial results with historical data. Growth in this metric confirms the commercialization efficiency of NaviCap capsules. Investors should interpret the upward vector as a signal of business scaling.